Welcome to our dedicated page for Astrotech news (Ticker: ASTC), a resource for investors and traders seeking the latest updates and insights on Astrotech stock.
Astrotech Corporation develops instrumentation businesses built around mass spectrometry and gas chromatography technologies through wholly owned subsidiaries. News about ASTC commonly covers 1st Detect and its TRACER 1000 trace detection systems for aviation security, explosives screening, and narcotics detection, including regulatory certifications, deployments, and security-market applications.
Company updates also address AgLAB process analyzers for agriculture products, Pro-Control industrial chemical process control, BreathTech breath-analysis work for volatile organic compounds, and EN-SCAN portable environmental GC-MS for field testing of air, water, and soil. Recurring releases include fiscal results, research and development progress, sales activity, leadership appointments, and board-level strategic or governance actions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Astrotech Corporation (Nasdaq: ASTC) announced its Q2 fiscal 2023 results, ending December 31, 2022, reporting a total revenue of $301,000, primarily from its TRACER 1000™ explosive trace detector and related services. The company’s gross margin improved to 38%, up from 18% in the previous year, attributed to higher-margin services. Key developments include the launch of the AgLAB 1000-D2™ for the cannabis industry, which could boost revenues by 45%, and the BreathTest-1000™, which can differentiate between infected and healthy breath samples. Astrotech’s cash and liquid investments stand at $46.8 million, and it successfully regained Nasdaq listing compliance.
Astrotech Corporation (Nasdaq: ASTC) has appointed Thomas B. Pickens III as Chief Technology Officer, complementing his role as CEO. This dual role highlights Pickens' expertise in advancing the company’s proprietary Astrotech Mass Spectrometer Technology (AMS Technology). Since 2017, he has played a crucial role in developing products such as the BreathTest-1000 for COVID-19 detection. Additionally, he is leading initiatives in essential oils distillation using AMS Technology. The company anticipates that this leadership change will enhance commercial value, although it faces uncertainties regarding FDA approvals for its products.
Astrotech Corporation (Nasdaq: ASTC) announced an expansion of its Board of Directors from four to five members, appointing Bob McFarland as a new director. McFarland brings extensive executive management experience, particularly in information technology, having served at the Department of Veterans Affairs as Chief Information Officer. His experience includes significant roles at Dell, where he managed government relations. The Board welcomes McFarland's expertise, particularly as Astrotech develops its mass-spectrometry technologies, including the BreathTest-1000, and navigates FDA approval processes.
Astrotech Corporation (Nasdaq: ASTC) announced the adoption of a limited-duration stockholder rights plan effective immediately, aimed at protecting the interests of all stockholders. This plan responds to significant accumulations of common stock, ensuring fair treatment and reducing the risk of hostile takeovers. The plan is set to last for 364 days, expiring on December 20, 2023, and is triggered if a person or group acquires 15% or more of the shares. The rights will be distributed to stockholders of record by January 5, 2023.